AU2015283805B2 - Helicobacter therapeutic - Google Patents

Helicobacter therapeutic Download PDF

Info

Publication number
AU2015283805B2
AU2015283805B2 AU2015283805A AU2015283805A AU2015283805B2 AU 2015283805 B2 AU2015283805 B2 AU 2015283805B2 AU 2015283805 A AU2015283805 A AU 2015283805A AU 2015283805 A AU2015283805 A AU 2015283805A AU 2015283805 B2 AU2015283805 B2 AU 2015283805B2
Authority
AU
Australia
Prior art keywords
htra
polypeptide
htra polypeptide
seq
pylori
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2015283805A
Other languages
English (en)
Other versions
AU2015283805A1 (en
Inventor
Philip Sutton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Murdoch Childrens Research Institute
Original Assignee
Murdoch Childrens Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2014902493A external-priority patent/AU2014902493A0/en
Application filed by Murdoch Childrens Research Institute filed Critical Murdoch Childrens Research Institute
Publication of AU2015283805A1 publication Critical patent/AU2015283805A1/en
Application granted granted Critical
Publication of AU2015283805B2 publication Critical patent/AU2015283805B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/105—Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. campylobacter, helicobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/121—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Helicobacter (Campylobacter) (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2015283805A 2014-06-30 2015-06-30 Helicobacter therapeutic Active AU2015283805B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2014902493 2014-06-30
AU2014902493A AU2014902493A0 (en) 2014-06-30 Helicobacter therapeutic
PCT/AU2015/000380 WO2016000022A1 (en) 2014-06-30 2015-06-30 Helicobacter therapeutic

Publications (2)

Publication Number Publication Date
AU2015283805A1 AU2015283805A1 (en) 2017-01-05
AU2015283805B2 true AU2015283805B2 (en) 2021-02-25

Family

ID=55018143

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015283805A Active AU2015283805B2 (en) 2014-06-30 2015-06-30 Helicobacter therapeutic

Country Status (9)

Country Link
US (3) US20170165347A1 (enExample)
EP (1) EP3160492A4 (enExample)
JP (1) JP6634444B2 (enExample)
KR (1) KR102481455B1 (enExample)
CN (2) CN113694191A (enExample)
AU (1) AU2015283805B2 (enExample)
BR (1) BR112016030728A2 (enExample)
RU (1) RU2017100658A (enExample)
WO (1) WO2016000022A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101885460B1 (ko) 2017-02-07 2018-08-03 두산중공업 주식회사 가스터빈용 프리 스월러 장치
CN108531468B (zh) * 2018-02-24 2020-07-17 广东工业大学 编码重组幽门螺杆菌丝氨酸蛋白酶的基因、卵黄抗体与应用
KR102500799B1 (ko) 2018-03-09 2023-02-20 삼성디스플레이 주식회사 트랜지스터 기판 및 이를 구비하는 표시 장치
RU2746590C1 (ru) * 2020-10-12 2021-04-16 Федеральное государственное бюджетное образовательное учреждение высшего образования "Вятский государственный университет" Способ эрадикации бактерий Helicobacter pylori при экспериментальном хеликобактериозе у конвенциональных белых мышей и средство для его осуществления

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999055871A1 (en) * 1998-04-23 1999-11-04 Smithkline Beecham Biologicals S.A. Polypeptides from moraxella (branhamella) catarrhalis
WO2001090383A2 (en) * 2000-05-25 2001-11-29 Aventis Pasteur Limited Co-expression of recombinant proteins
WO2002059148A2 (en) * 2001-01-26 2002-08-01 Intercell Ag A method for identification, isolation and production of antigens to a specific pathogen
WO2004094467A2 (en) * 2003-04-22 2004-11-04 Intercell Ag H. pylori antigens
WO2007087576A2 (en) * 2006-01-24 2007-08-02 The Uab Research Foundation Compositions and methods for the identification and treatment of immune-mediated inflammatory diseases
WO2009026615A1 (en) * 2007-08-24 2009-03-05 University Of Wollongong Group a streptococcus pharmaceutical compositions and methods thereof
WO2010068413A1 (en) * 2008-11-25 2010-06-17 Emergent Product Development Gaithersburg Inc. Chlamydia vaccine comprising htra polypeptides

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5643578A (en) 1992-03-23 1997-07-01 University Of Massachusetts Medical Center Immunization by inoculation of DNA transcription unit
DE69536091D1 (de) 1994-01-27 2010-09-09 Univ Massachusetts Medical Immunisierung durch Impfung von DNS Transkriptionseinheit
US5939400A (en) 1996-02-26 1999-08-17 The Board Of Trustees Of The Leland Stanford Junior University DNA vaccination for induction of suppressive T cell response
AU3210997A (en) 1996-05-24 1997-12-09 University Of Maryland At Baltimore Dna vaccines for eliciting a mucosal immune response
CA2288211A1 (en) * 1997-04-25 1998-11-05 Genelabs Technologies, Inc. Antigenic composition and method of detection for helicobacter pylori
IT1298087B1 (it) 1998-01-08 1999-12-20 Fiderm S R L Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni
US6585975B1 (en) * 1998-04-30 2003-07-01 Acambis, Inc. Use of Salmonella vectors for vaccination against helicobacter infection
AUPP684998A0 (en) * 1998-10-30 1998-11-26 Murdoch Institute for Research into Birth Defects Limited, The A method of recombination and agents useful for same
US6319224B1 (en) 1999-08-20 2001-11-20 Bioject Medical Technologies Inc. Intradermal injection system for injecting DNA-based injectables into humans
US6494865B1 (en) 1999-10-14 2002-12-17 Becton Dickinson And Company Intradermal delivery device including a needle assembly
DE60124526D1 (de) * 2000-04-27 2006-12-28 Max Planck Gesellschaft Methode zur identifizierung von helicobacter antigenen
GB0103170D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
FR2815544B1 (fr) 2000-10-23 2003-02-14 Poudres & Explosifs Ste Nale Seringue sans aiguille securisee a architecture compacte
EP2004678A1 (en) * 2006-03-15 2008-12-24 Csir Modulation of glutamine synthetase activity

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999055871A1 (en) * 1998-04-23 1999-11-04 Smithkline Beecham Biologicals S.A. Polypeptides from moraxella (branhamella) catarrhalis
WO2001090383A2 (en) * 2000-05-25 2001-11-29 Aventis Pasteur Limited Co-expression of recombinant proteins
WO2002059148A2 (en) * 2001-01-26 2002-08-01 Intercell Ag A method for identification, isolation and production of antigens to a specific pathogen
WO2004094467A2 (en) * 2003-04-22 2004-11-04 Intercell Ag H. pylori antigens
WO2007087576A2 (en) * 2006-01-24 2007-08-02 The Uab Research Foundation Compositions and methods for the identification and treatment of immune-mediated inflammatory diseases
WO2009026615A1 (en) * 2007-08-24 2009-03-05 University Of Wollongong Group a streptococcus pharmaceutical compositions and methods thereof
WO2010068413A1 (en) * 2008-11-25 2010-06-17 Emergent Product Development Gaithersburg Inc. Chlamydia vaccine comprising htra polypeptides

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HOY, B. et al., "Helicobacter pylori HtrA is a new secreted virulence factor that cleaves E cadherin to disrupt intercellular adhesion''.", EMBO REPORTS, (2010), vol. 11, no. 10, ISSN 1469-221x, pages 798 - 804 *

Also Published As

Publication number Publication date
KR20170016989A (ko) 2017-02-14
JP6634444B2 (ja) 2020-01-22
JP2017521490A (ja) 2017-08-03
BR112016030728A2 (pt) 2018-02-20
CN106573038A (zh) 2017-04-19
RU2017100658A (ru) 2018-07-30
EP3160492A1 (en) 2017-05-03
US20200108135A1 (en) 2020-04-09
US11819546B2 (en) 2023-11-21
US20220193216A1 (en) 2022-06-23
US20170165347A1 (en) 2017-06-15
RU2017100658A3 (enExample) 2019-02-19
EP3160492A4 (en) 2018-01-03
WO2016000022A1 (en) 2016-01-07
KR102481455B1 (ko) 2022-12-26
CN113694191A (zh) 2021-11-26
AU2015283805A1 (en) 2017-01-05

Similar Documents

Publication Publication Date Title
US11819546B2 (en) Helicobacter therapeutic
AU2011298306B2 (en) Isolated polypeptide of the toxin A and toxin B proteins of C. difficile and uses thereof
JP2017518367A (ja) ストレプトコッカス・スイス感染に対するワクチン組成物
JP6632974B2 (ja) フェノール可溶性モジュリン、δ毒素、スーパー抗原に由来するトキソイドペプチド、およびその融合物
Liu et al. Therapeutic efficacy of oral immunization with a non-genetically modified Lactococcus lactis-based vaccine CUE-GEM induces local immunity against Helicobacter pylori infection
US11834684B2 (en) Vaccine for immunocompromised hosts
AU2013203774A1 (en) Compositions and methods for immunization against bacteria expressing a carbapenemase
AU2011310887A1 (en) Combination of an agonistic anti-CD40 monoclonal antibody or a CD40 ligand and inactivated or attenuated bacteria for use in the treatment and/or prevention of mastitis
JP7181208B2 (ja) ワクチン構築物およびブドウ球菌感染症に対するその使用
CN115151559A (zh) 葡萄球菌肽和使用方法
JP2021523908A (ja) 連鎖球菌毒素性ショック症候群
WO2011018779A1 (en) Modified helicobacter protein
WO2009144240A1 (en) Composition and method for the assay and treatment of anthrax
EP2004222A2 (en) Vaccine
Ozberk Design and evaluation of novel liposome-based peptide vaccines for improved efficacy against group A streptococcal infections of the mucosa and skin
Eyles et al. Concomitant administration of Yersinia pestis specific monoclonal antibodies with plague vaccine has a detrimental effect on vaccine mediated immunity
HK1238144B (zh) A群链球菌疫苗
JP2014515594A (ja) Ｃｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅ抗原
HK1197887A (en) Isolated polypeptide of the toxin a and toxin b proteins of c. difficile and uses thereof
HK1197887B (en) Isolated polypeptide of the toxin a and toxin b proteins of c. difficile and uses thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)